M.C. Liu
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
-
- Cancer Genomics and Diagnostics
Papers in
- Oncology 6
- Cancer Cells and Metastasis 3
- Cancer Immunotherapy and Biomarkers 2
- Colorectal Cancer Surgical Treatments 1
- Colorectal Cancer Treatments and Studies 1
- HER2/EGFR in Cancer Research 1
-
- Cancer Genomics and Diagnostics 5
- Co-authors
- Sylvia Adams (1 shared paper)Rita Nanda (2 shared papers)Sherene Loi (1 shared paper)Deborah Toppmeyer (1 shared paper)Antoinette R. Tan (1 shared paper)Kenji Tamura (1 shared paper)Lin Jia (1 shared paper)Yu Ding (1 shared paper)
- Journals
- Annals of Oncology (3 papers)ESMO Open (2 papers)Journal of Thoracic Oncology (1 paper)Cancer Research (1 paper)
- Partner nations
- United StatesItalyAustralia
In The Last Decade
M.C. Liu
4 papers receiving 486 citations
Hit Papers
Peers
Comparison fields: 5 of 42
- Oncology 418
- Cancer Research 126
- Immunology 159
- Pulmonary and Respiratory Medicine 158
- Pathology and Forensic Medicine 24
Countries citing papers authored by M.C. Liu
This map shows the geographic impact of M.C. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.C. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.C. Liu more than expected).
Fields of papers citing papers by M.C. Liu
This network shows the impact of papers produced by M.C. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.C. Liu. The network helps show where M.C. Liu may publish in the future.
Co-authors
The 25 scholars most cited alongside M.C. Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 460 |
| 2 | 2019 | 25 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 0 |
About M.C. Liu
M.C. Liu is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 7 papers that have together received 490 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (5 papers), Genetic factors in colorectal cancer (4 papers), Cancer Cells and Metastasis (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Colorectal Cancer Surgical Treatments (1 paper), Colorectal Cancer Treatments and Studies (1 paper), HER2/EGFR in Cancer Research (1 paper) and Epigenetics and DNA Methylation (1 paper). The work is most often cited by research in Oncology (418 citations), Cancer Research (126 citations), Immunology (159 citations), Pulmonary and Respiratory Medicine (158 citations) and Pathology and Forensic Medicine (24 citations). M.C. Liu has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Sylvia Adams, Rita Nanda, Sherene Loi, Deborah Toppmeyer, Antoinette R. Tan, Kenji Tamura, Lin Jia, Yu Ding, Eric P. Winer and Vassiliki Karantza. Their work appears in journals such as Annals of Oncology, ESMO Open, Journal of Thoracic Oncology and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.